Infectologia Pediátrica
Relatório CDC | Segurança da vacina contra COVID-19 em crianças de 5 a 11 anos de idade.
10 Jan, 2022 | 12:49hComentário: COVID-19 vaccine appears safe in children aged 5–11 Years – News Medical
Comentário no Twitter
Early vaccine safety data for children ages 5–11 years old found that reactions such as fatigue and headaches were commonly reported following Pfizer-BioNTech #COVID19 vaccine. Everyone ages 5 years & older should get vaccinated as soon as possible. https://t.co/D66QgLRWni pic.twitter.com/8I48L5GmcG
— MMWR (@CDCMMWR) December 30, 2021
Estudo CDC | Uma estratégia de testar para ficar (permitindo que contatos próximos de infectados por COVID-19 permaneçam na escola) foi muito eficaz em evitar progressão da disseminação na escola e permitiu que as crianças continuassem em sala de aula como uma alternativa à quarentena domiciliar.
10 Jan, 2022 | 12:46hEstudo CDC relacionado: Evaluation of a Test to Stay Strategy in Transitional Kindergarten Through Grade 12 Schools — Los Angeles County, California, August 16–October 31, 2021 – CDC Morbidity and Mortality Weekly Report
Diretrizes CDC relacionadas:
What You Should Know About COVID-19 Testing in Schools – Centers for Disease Control and Prevention
Comentário: ‘Test-to-stay’ works to keep students in school safely, CDC director says – CNN
Conteúdos relacionados:
Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay.
Opinion | Data from routine Covid testing can help schools stay open this year.
Comentário no Twitter
Although vaccination is the best way to protect against #COVID19 for those aged 5 and up, schools might consider Test to Stay strategy for allowing close contacts who are not fully vaccinated to remain in the classroom. Learn more in a new @CDCMMWR: https://t.co/3m64vomRDh. pic.twitter.com/AAENAdxJ1y
— CDC (@CDCgov) December 17, 2021
[Preprint] Risco de miocardite após vacinações sequenciais contra COVID-19 por idade e sexo.
10 Jan, 2022 | 12:43hRisk of myocarditis following sequential COVID-19 vaccinations by age and sex – medRxiv
Nota: este estudo é uma análise atualizada de um estudo recente, publicado na revista Nature Medicine; ver abaixo:
Nova diretriz AAP recomenda o rastreamento de rotina para HIV para todos os jovens de 15 anos ou mais.
10 Jan, 2022 | 12:20hComentário: Pediatricians Can Play Key Role in HIV Testing, Prophylaxis – HealthDay
Estudo randomizado | Tratamento antirretroviral de baixo custo e de fácil adesão, baseado em dolutegravir, como terapia de primeira ou segunda linha foi não inferior ao tratamento padrão da infecção por HIV-1 em crianças.
10 Jan, 2022 | 12:13hDolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário: Easy-to-take medicine better at suppressing HIV in children – University College London
Comentários no Twitter
Dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART. https://t.co/PP0XaEVswO pic.twitter.com/pQvhjdXcUk
— NEJM (@NEJM) December 29, 2021
Visual Abstract: Dolutegravir as First- or Second-Line HIV Treatment in Children https://t.co/2RIg9uH2V1 pic.twitter.com/mDr1Z6l6CJ
— NEJM (@NEJM) January 4, 2022
Diretriz NICE | Febre em menores de 5 anos: avaliação e tratamento.
17 Dez, 2021 | 12:12hConteúdo relacionado: AAP Guideline: Evaluation and management of well-appearing febrile infants 8 to 60 days old.
Sepse em crianças: estado da arte do tratamento.
16 Dez, 2021 | 12:53hSepsis in children: state-of-the-art treatment – Therapeutic Advances in Infectious Disease
Antibióticos em crianças gravemente doentes – Uma revisão narrativa sobre os diferentes aspectos de uma abordagem racional.
16 Dez, 2021 | 12:52hRiscos de miocardite, pericardite e arritmias cardíacas associadas à vacinação contra COVID-19 vs. infecção por SARS-CoV-2.
15 Dez, 2021 | 12:45hComunicado de imprensa: COVID-19 infection, more likely than vaccines, to cause rare cardiovascular complications – University of Oxford
Comentários no Twitter
Hugely important work from @JuliaHCox and colleagues:
In people <40, Pfizer carries a much lower risk of myocarditis than either Moderna **or SARS-CoV-2 infection** (annotations added)https://t.co/wqRts3ALqy pic.twitter.com/fnn1T39h1b
— David Juurlink (@DavidJuurlink) December 14, 2021
A case series published in @NatureMedicine shows an increased risk of myocarditis after receiving the Astra-Zeneca-Oxford, Pfizer-BioNTech and the Moderna COVID-19 vaccines, but SARS-CoV-2 infection carried a greater risk of myocarditis. https://t.co/6y7pZlJN70 pic.twitter.com/cBlKz9sUkg
— Nature Portfolio (@NaturePortfolio) December 14, 2021
Just published @NatureMedicine
The most comprehensive assessment of the rare events of myocarditis, pericarditis, arrhythmias after COVID and AZ, mRNA vaccineshttps://t.co/0bEdMJSLXg pic.twitter.com/eC5JOx0CmG— Eric Topol (@EricTopol) December 14, 2021
Revisão sistemática | Antibióticos para adultos e crianças com dores de garganta.
10 Dez, 2021 | 11:05hResumo: Antibiotics for adults and children with sore throats – Cochrane Library
Pesquisa original: Antibiotics for treatment of sore throat in children and adults – Cochrane Library